Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fusion protein of thymulin alpha1

A technology of fusion protein and thymosin, which is applied in the field of fusion protein of thymosin α1, can solve the problems of short half-life and low immune resistance of tumor sites, and achieve long half-life in vivo and strong anti-tumor effect

Inactive Publication Date: 2016-06-15
CHINA PHARM UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the existing clinically used thymosin α1 has shortcomings such as short half-life stimulation or low immune resistance at the tumor site

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein of thymulin alpha1
  • Fusion protein of thymulin alpha1
  • Fusion protein of thymulin alpha1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Embodiment 1 Construction of thymosin α1 fusion protein expression vector

[0027] Use the method of gene synthesis to obtain the complementary sequence of the nucleotide sequence corresponding to SEQIDNO: 1 and SEQIDNO: 3. NcoI and HindIII enzyme cutting sites are designed at both ends of the SEQIDNO: 5 sequence, and the 5' of NcoI and HindIII enzyme cutting sites Three guanine protection bases were designed at each end, the complementary sequence was denatured at 94°C for 5 minutes, annealed at 54°C for 10 minutes, then digested with NcoI and HindIII, cloned into the prokaryotic expression vector pET32a, transformed into Escherichia coli, and polymerase chain method Screen for positive transformants. The polymerase chain method primers are:

[0028] P1: 5'-CCATGGCTAGCGATGCGGCCGTGGAT-3' SEQ ID NO: 6

[0029] P2: 5'-AAGCTTTTATTTACCCGGAGACAGGG-3' SEQ ID NO: 7

[0030] The polymerase chain method amplification system is:

[0031] 10 μl each of primer P1 (25 μmol / L) an...

Embodiment 2

[0033] Induction and separation and purification of the recombinant protein of embodiment 2

[0034] Inoculate the recombinant bacteria from the single bacterium colony on the plate line to 5ml of LB medium, shake overnight, inoculate into 500ml of ampicillin-resistant liquid LB medium with 1% (V / V) inoculation amount, shake at 37 degrees After incubation for 2.5 hours, when OD600 is about 0.6, add 1% (V / V) 0.5mol / L lactose and shake for 1, 2, 3, 4 hours to induce the expression of the target protein, and detect it by electrophoresis, see figure 1 . Centrifuge at 13,000 rpm at 4 degrees for 10 minutes to collect the bacteria, add 20 times the volume of the bacteria in buffer (20mmol / L sodium phosphate at pH7.4, 0.5mol / LNaCl) to suspend the bacteria, and then perform ultrasonication in an ice bath Break up the bacterium, then centrifuge at 13000 rpm at 4 degrees for 10 minutes, draw the supernatant and load it on a metal chelate chromatography column, first use 10 times the co...

Embodiment 3

[0035] Example 3 Anti-melanoma Experiment in Animals

[0036] Murine melanoma B16F10 cells were digested with 0.05% trypsin and centrifuged at 1000rpm for 5 minutes, resuspended in PBS, adjusted to 5,000,000 cells per ml, and subcutaneously inoculated on the side of C57BL / 6 (6-8 weeks) mice for about 500,000 cells. When the average tumor volume reaches 100mm 3, randomly divide the mice into 4 groups, 8 mice / group, except the negative control PBS group and the positive control paclitaxel group, one group is given thymosin α1 (dose is 0.25mg / kg / d), and one group is given thymosin α1 fusion protein (The dose is 0.25mg / kg / d, which is in an equimolar relationship with the dose of thymosin α1). kg). The final therapeutic effect is expressed by tumor weight inhibition rate: (1-tumor tumor weight in treatment group / tumor tumor weight in negative control group)×100%

[0037] The result is as figure 2 As shown, when treated to the 11th day, the tumor inhibition rate of thymosin α1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses fusion protein of thymulin alpha1. The fusion protein is formed by connecting the thymulin alpha1 or active fragments of the thymulin alpha1with a constant region of immune globulin through connecting peptide or directly. The fusion protein can be expressed in eukaryotic cells and can also be expressed in prokaryotic cells. According to the fusion protein of the thymulin alpha1, a pronucleus carrier containing a target gene is prepared through the recombination DAN technology and expressed, separated and purified in escherichia coli, and compared with archetype thymulin alpha1, the obtained fusion protein of the thymulin alpha1 is longer in in-vivo half-life period and more efficient in anti-tumor effect.

Description

technical field [0001] The invention belongs to the technical field of bioengineering and pharmacy, and in particular relates to a fusion protein of thymosin α1. Background technique [0002] Thymosin α1 is a small-molecule active polypeptide with immunomodulatory effects. Goldstein isolated and purified a small-molecule biologically active polypeptide from thymopoietin 5 component (TF5) in the late 1970s, which has a thymosin-like biological Activity, named thymosin α1, it consists of 28 amino acids, Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys- Glu-Lys-Lys-Glu-Val-Val-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH. Thymosin α1 has been widely used clinically, mainly for primary and secondary immunodeficiency diseases, such as chronic hepatitis B, severe hepatitis B, antiviral treatment of AIDS, etc., as well as pre-chemotherapy and radiotherapy for various malignant tumors adjuvant medication. However, the currently clinically used thymosin α1 has disadvan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00A61K38/22A61K47/48A61P35/00A61P1/16A61P31/18
CPCA61K38/00C07K14/57581C07K2319/30Y02A50/30
Inventor 劳兴珍郑珩李晴晴于婷婷
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com